Human immunodeficiency virus type 1 Vpr: oligomerization is an essential feature for its incorporation into virus particles
© Venkatachari et al; licensee BioMed Central Ltd. 2010
Received: 28 February 2010
Accepted: 7 June 2010
Published: 7 June 2010
HIV-1 Vpr, a nonstructural viral protein associated with virus particles, has a positive role in the efficient transport of PIC into the nucleus of non-dividing target cells and enhances virus replication in primary T cells. Vpr is a 96 amino acid protein and the structure by NMR shows three helical domains. Vpr has been shown to exist as dimers and higher order oligomers. Considering the multifunctional nature of Vpr, the contribution of distinct helical domains to the dimer/oligomer structure of Vpr and the relevance of this feature to its functions are not clear. To address this, we have utilized molecular modeling approaches to identify putative models of oligomerization. The predicted interface residues were subjected to site-directed mutagenesis and evaluated their role in intermolecular interaction and virion incorporation. The interaction between Vpr molecules was monitored by Bimolecular Fluorescence complementation (BiFC) method. The results show that Vpr forms oligomers in live cells and residues in helical domains play critical roles in oligomerization. Interestingly, Vpr molecules defective in oligomerization also fail to incorporate into the virus particles. Based on the data, we suggest that oligomerization of Vpr is essential for virion incorporation property and may also have a role in the events associated with virus infection.
HIV-1 vpr gene encodes a protein of 96 amino acids with a predicted molecular weight of 14 kDa, which is conserved in both HIV and SIV . Vpr is packaged into assembling virions by binding to the p6 domain of viral p55Gag precursor protein. The presence of a functional Vpr is necessary for the efficient translocation of the pre-integration complex (PIC) into the nucleus and subsequent infection of primary monocytes/macrophages and other non-dividing cells [2–4]. Analysis of HIV-1 accessory genes (including vpr) in long-term non-progressors and asymptomatic patients suggests that defects in accessory genes are related to non-progressive status [5, 6]. In this regard, the presence of defective or mutated vpr quasispecies has been shown to be associated with long-term non-progressive mothers [6–8]. Though vpr is selected against in tissue culture, selection for an intact Vpr occurs in vivo [9, 10]. This finding suggests that vpr is required for optimal virus production and pathogenesis in vivo . These observations clearly indicate the importance of Vpr in viral pathogenesis and disease progression.
HIV-1 Vpr is known to oligomerize both in vitro and in vivo [12, 13]. This has been demonstrated by using cells in which Vpr was expressed either in the context of transfection of plasmid DNAs or through virus infection. Similar observations have also been reported with the purified Vpr protein generated using the prokaryotic expression system. Vpr has been shown to exist as dimers, trimers, tetramers and higher order multimers . In general, protein oligomerization is thought to be an advantageous feature for the stability of the protein, interaction/binding with other proteins, allosteric control and the establishment of higher-order complexity . HIV-1 Vpr, a non-structural protein, is incorporated into the virus particles and possesses several characteristic features that are known to play important roles in HIV-1 replication and disease progression. Vpr interacts with both viral and cellular host proteins, which are essential for Vpr-mediated functions. For instance, Vpr interacts with Gag-p6 and packages in the virus particles and virion-incorporated Vpr is known to positively regulate infection of non-dividing cells and enhance virus production in T cells [4, 11, 15, 16]. However, it is not clear whether oligomerization of Vpr is required for virion incorporation and/or for its interactions with cellular proteins.
Vpr also has a well-defined role in apoptosis, cell cycle arrest and dysregulation of immune functions [17–19]. Many of the Vpr functions are carried out by virion-associated Vpr similar to de novo synthesized Vpr, suggesting that incorporation of Vpr into virus particles is an important event in HIV-1 biology. While the structure of Vpr based on X-ray crystallography is not yet available, biochemical analysis and NMR studies suggest that Vpr is composed of three alpha helices connected by loops [13, 20–22]. Site-directed mutagenesis studies targeting single residues in Vpr indicated that amino acids in the N terminal region including the helical domains are essential for stability and virion incorporation and a region comprising the Helix III and the C terminal region determines the nuclear transport of Vpr [23–26]. With respect to oligomerization, it has been suggested that a leucine-zipper type mechanism is likely involving helix III based on the analysis of a peptide corresponding to the C-terminal region by NMR . However, the structure of helix III in the peptide is different from that observed in the full-length protein . Furthermore, mutagenesis studies have implicated additional amino acids in the hydrophobic core of the protein  in addition to a direct role for residue 44 in oligomerization through deletion. Thus, the roles of specific domains and residues involved in oligomerization are not yet defined.
To gain a better understanding of Vpr oligomerization and its role in virion association, we have utilized Bimolecular Fluorescence complementation (BiFC) analysis. This involves a chimeric protein strategy in which HIV-1 Vpr is fused to either N- or C-terminus fragment of the Venus protein. Upon expression and formation of dimers in live cells the Venus will emit fluorescence that can be detected by microscopy and flow cytometry. Such an approach combined with specific alterations in Vpr based on NMR structure and modeling have allowed us to evaluate the domains and residues essential for Vpr oligomerization and its relevance in virion incorporation. The results from the studies presented here indicate that Vpr molecules with distinct mutations in helical domains I, II and III dysregulate Vpr oligomerization and alter the ability of Vpr to incorporate into virus particles.
Materials and Methods
Cells and plasmid
HeLa, and 293T cells were grown in DMEM supplemented with 10% FCS, 1% glutamine and 1% penicillin-streptomycin. HeLa cells were obtained from NIH, AIDS reagent program. Proviral construct pNL43ΔVpr was generated by mutating the start codon of Vpr and verified by sequencing and westernblot analysis. Vpr expression plasmids were generated as described before . All the mutant constructs were sequenced to verify the integrity of the mutations. For BiFC assays, sequences encoding the amino (residues 1 to 173, VN) or carboxyl (residues 155 to 238, VC) fragments of Venus fluorescence protein (template generously provided by Dr. Ronald Montelero, University of Pittsburgh) were fused to the N terminus of HIV-1 Vpr via a six-alanine linker and HA-tag for detection. All plasmids were isolated using a QIAGEN Maxiprep kit (QIAGEN, Valencia, CA), and the specific mutations were confirmed by DNA sequencing.
Vpr dimer interface using docking model
Structural dimer models of Vpr were generated using ClusPro [29, 30] and RosettaDock software  based on the full length monomer NMR structure of Vpr (PDB id:1m8l) . First an approximate orientation of the dimer was obtained using the ClusPro server. The homo-multimeric docking option and DOT method [32, 33] starting with 25000 initial conformations were employed. Of the resulting 10 best docking conformations, two models comprising antiparallel and parallel conformation based on best fit to the experimental data were selected. Each of these conformations was used as input into the Rosetta Dock server as the starting conformations for refinement via local docking of . The hexamer model was generated using Cluspro server based on the monomer structure that comprised residues 15-78. The flexible N and C-termini were excluded since their inclusion resulted in unfeasible structural models where N and C termini formed the interface. All models are available upon request.
Expression of Vpr molecules by immunoblot
HEK293T cells were cotransfected with Vpr expression plasmid using L Lipofectamine. Forty-eight hours post-transfection, Cells were washed twice with PBS and lysed in RIPA buffer containing 50 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton X-100, 1 mM sodium orthovanadate, 10 mM sodium fluoride, 1.0 mM phenylmethylsulfonyl fluoride, 0.05% deoxycholate, 10% sodium dodecyl sulfate, aprotinin (0.07 trypsin inhibitor unit/ml), and the protease inhibitors leupeptin, chymostatin, and pepstatin (1 μg/ml; Sigma). Cell lysates were clarified by centrifugation, and total cell lysates (50 μg) were separated on a 12% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) electrophoresis gel, transferred, and immunoblotted with anti-HIV-1 p24 for Gag and anti-HA for Vpr. The blots were developed using an ECL kit (Amersham Biosciences, Piscataway, NJ).
BiFC Flow cytometry
Thirty-six hours post transfection 293T cells were washed with PBS and fixed in 3.7% formaldehyde at room temperature for 15 minutes, and washed and resuspended in 200 μl of FACS buffer. Samples were analyzed using Epics-XL (Beckman Coulter, Miami, FL) with minimum of 40000 gated events acquired for each sample, and percent BiFC positive cells was calculated using Flow Jo software.
HeLa cells were used to perform all immunofluorescence and microscopy assays. Thirty-six hours post transfection, cells were washed with PBS and fixed in 3.7% formaldehyde at room temperature for 10 minutes, and washed and permeabilized with 0.5% Triton X-100 for an additional 10 minutes. After washing 3 times with PBS, cells were blocked with 5% BSA at room temperature for 1 hour followed by incubation with primary antibody (HA or Vpr; 1:200 dilution) for 1 hour at room temperature and incubated with rabbit anti-mouse or mouse anti-rabbit IgG Rhodamine (RRX) (1:400; Jackson ImmunoResearch, West Grove, PA) for 1 hour at room temperature. Cells were mounted with VECTASHIELD mounting media containing DAPI (Vector Laboratories, Burlingame, CA). Immunofluorescence analysis was performed using a fluorescence microscope with Nikon SPOT camera (Fryer, Huntley, IL) and images were processed using MetaMorph software (Universal Imaging Corporation, Downington, PA).
Vpr-Gag interaction by BiFC and virion incorporation
Oligomerization of Vpr in live cells was evaluated by BiFC methods. HeLa cells were seeded in 6-well plates with glass slides and transfected with combinations of Vprwt, Vpr mutants and Gag expression plasmids with their respective VN or VC combinations or with control plasmids using Lipofectamine. Forty hours post-transfection, cells were washed with PBS and fixed with 2% paraformaldehyde. Cells were mounted with VECTASHIELD containing DAPI (Vector Laboratories, CA) and fluorescence was detected using Nikon inverted fluorescence microscope with appropriate filters. The remaining cells in the plates were analyzed by flow cytometry followed by cell quest software to measure the percent fluorescent positive cells. Ability to Vpr mutants to interact with Gag and package into virus particles was assessed by monitoring the presence of Vpr in virus particles. Briefly, cells were cotransfected with pGag and pVpr mutants or vector plasmid as described before. Forty hours post transfection, supernatant was collected, spun at 2000 rpm to remove cell debris and passed through 0.22 μM filter to remove aggregates and cell debris. Filtered supernatant was ultracentrifuged to pellet the virus particles and used in SDS-PAGE followed by immunoblot with anti-Gag (p24) and anti-Vpr antibody. Similarly, cells were pelleted and cell lysates were used to detect the presence and expression of Gag and Vpr in transfected culture.
Construction and characterization of chimeric Vpr for oligomerization studies using BiFC analysis
Structure-based prediction of the Vpr dimer and oligomeric interfaces
HIV-1 Vpr residues involved in dimerization based on dimer models
Parallel dimer model
Secondary structure unit
Residues in the interface
Antiparallel dimer model
Secondary structure unit
Residues in the interface
Role of predicted interface residues in Vpr oligomerization
Next, we assessed the ability of Vpr mutants to form oligomers by BiFC analysis. The expression of Vpr molecules was also assessed from the same batch of cells by indirect immunofluorescence using HA antibody (to detect HA tagged Vpr) and compared with BiFC by microscopy (Fig. 4C). Results indicate that Vprwt, E48A and R80A exhibited 35, 22 and 39% BiFC positive cells respectively, whereas mutants A30L, Δ44, L68E and H71R did not show BiFC positive cells, suggesting that these mutants are defective in oligomerization. The differences in percent BiFC in Vprwt, E48A and R80A is due to difference in transfection efficiency and did not show statistical significance in multiple experiments. Importantly, staining for Vpr (panel Vpr in Fig. 4C) further confirmed the expression of Vpr protein suggesting that lack of dimerization is not due to lack of Vpr expression. We also assessed whether subcellular distribution of Vpr mutant molecules has any role in oligomerization. Both Vprwt, and E48A showed uniform nuclear localization. The Vpr mutant R80A exhibited nuclear membrane distribution of venus fluorescence. On the other hand, BiFC negative mutants, A30L, Δ44, L68E and H71R showed both nuclear and cytoplasmic distribution suggesting that subcellular distribution of Vpr is different in oligomerization defective mutants in comparison to Vprwt. Similar results were reported by other groups indicating that nuclear localization of Vpr is not absolutely necessary for Vpr mediated functions such as cell cycle arrest and virion incorporation [26, 36].
Relevance of oligomerization in Vpr-Gag interaction and virion incorporation of Vpr
Next, we assessed the ability of Vpr mutants to incorporate into virus particles. HEK293T cells were cotransfected with pNL43Δvpr proviral plasmid and Vpr expression plasmids or vector control. Vpr amount in cell lysate was quantitated by loading protein normalized for transfection efficiency and amount of Vpr in virus particles was quantitated by loading viral lysates normalized using Gag-p24 antigen, respectively (Fig. 5B). Presence of Vpr in virus particles was noted only in Vprwt, E48A and R80A, whereas, A30L, Δ44, L68E and H71R did not show virion associated Vpr. However, all mutants showed equal amount of p24-Gag in the same sample. These results suggest that mutants A30L, Δ44, L68E and H71R are defective in virion incorporation and they did not alter/interfere with the virus production in the cells contransfected with NL43Δvpr proviral DNA and Vpr encoding plasmid. To further confirm that the lack of Vpr in virus particles is not due to lack of Vpr expression in these cells, cell lysates from the same samples were assessed for Vpr and p24 levels (data not shown). The results indicate that comparable levels of Vpr and p24 were observed in all cell lysates (Fig. 4B). Together theses studies indicate that Vpr oligomerization is an essential feature for virion incorporation.
Percent BiFC positive cells in wells transfected with a combination of Vpr and Gag expression plasmids.
HIV-1 and 2 are members of lentivirus family of retroviruses and are grouped as complex retroviruses. The unique feature of this group in comparison to simple retroviruses is that the viral genome codes for several proteins in addition to the core structural proteins. In this regard, HIV-1 is known to code for six auxiliary proteins (Vif, Vpr, Tat, Rev, Vpu and Nef) besides the structural proteins. Previous studies have demonstrated that auxiliary proteins play an essential role in HIV-1 replication and pathogenesis . Our laboratory has been interested for several years in evaluating the contribution of auxiliary proteins including Vpr. In this study, we have analyzed the requirement of sequences in Vpr essential for oligomerization feature of Vpr and its relevance to the functions of Vpr. Specifically, Vpr shares this feature with other auxiliary proteins such as Vif, Rev, Vpu, and Nef.
HIV-1 Vpr is a small oligomeric protein that plays an important role in HIV pathogenesis [5, 17, 19, 23, 42]. The underlying reasons for the selection of Vpr for the present studies are the following: (i) Vpr is a virion associated protein; (ii) Vpr plays a critical role for the replication of virus in macrophages and positively regulates viral replication in T cells; (iii) Vpr is a transcriptional activator of HIV-1 and heterologous cellular genes; (iv) Vpr inhibits proliferation of cells at G2/M phase; (v) Vpr induces apoptosis in diverse cell types including T cells and neurons; (vi) Vpr exhibits immune suppressive effects. Further, studies from non human primates and analysis of viral genes in long term non progressors suggest a correlation between defective Vpr and delayed progression of the disease [5, 43, 44]. More importantly, several Vpr-mediated functions are known to be induced by both cell-associated and virion-associated Vpr [17, 18, 45]. Together these studies point out the biological significance of virion associated factors and its role in early events associated with virus infection. Therefore, understanding the role of oligomerization in Vpr functions and disease progression may provide useful information for the development of therapeutics against HIV-1 targeting Vpr.
The oligomerization feature of Vpr was evaluated by using a complementation system based on Venus protein as a reporter. A strategy involving the generation of chimeric Venus-Vpr protein has allowed us to monitor oligomerization in live cells. This system has the sensitivity to detect Vpr-Vpr and Vpr-Gag interactions. Studies on the oligomerization of Vpr, analyzed by site-specific mutagenesis, identified some residues located in specific domains of Vpr. However, there is no information available regarding the dimer interface structure of Vpr. To address this, we have utilized the available NMR structure and modeling approaches to identify the residues that form putative dimer and oligomer interfaces of Vpr. Deletion of residue at position 44, which is predominantly glutamine (Q), is known to be oligomerization defective and was used as a control in these experiments. We reasoned that moderate replacements, in particular those mostly affecting size, should show significant biological effects if these residues form part of the interfaces. Thus, for A30 and L68 we chose L and E replacements, respectively, conserving hydrophobicity but changing the size of the position. On the other hand, at position H71, we chose R, maintaining the positive charge. Mutant Vpr molecules were generated containing alterations in the selected residues. The results regarding the expression and steady state level of Vpr indicated that mutants lacking the ability to oligomerize exhibit a pattern similar to that of wild type Vpr. This observation suggests that monomeric Vpr molecules are stable in cells, which is in agreement with an earlier report .
To interpret the mutagenesis data in structural terms, we created structural models of the Vpr dimer and oligomers through molecular docking based on the available full length monomer structure . Our models are shown in Figure 3, highlighting the positions of the residues that resulted in oligomerization defective properties of Vpr in vivo. The docked models revealed propensities for both parallel and antiparallel orientations of the monomers within a dimer indicating that both of the conformations are plausible. Regardless of orientation, helices II and III constitute the dimer interface in the majority of the models. In the parallel orientation, residues 30, 44, 68, 71, all of which fail to oligomerize when mutated, even with the conservative substitutions chosen, were part of the interface; while in the antiparallel orientation residues 44, 68 and 71 contributed to the binding energy in the interface. Further supporting our predicted interfaces, recent studies of Vpr mutants I60A and I67A indicated that these residues play a major role in trafficking the Vpr to the nuclear rim . Both of these residues are part of the interface in the predicted parallel conformation, whereas I60 is part of the antiparallel model. In agreement with the experimental results presented here suggest that both of these two dimer conformations are likely to occur in vivo. The parallel orientation fits the experimental data better, but further studies will be needed to fully differentiate between the two models. Furthermore, assays are needed that can clearly distinguish dimers from higher order oligomers. Based on the combined modeling and experimental results, we propose that dimerization primarily involves helices II and III, while oligomerization includes helix I also. The fact that the Vpr mutation A30L reported here and the recently studied nuclear rim localization defective mutant L23F  are located in helix I supports the proposed role of helix I in oligomerization. We predict that because helix I in the dimer models faces away from the dimer interface, it may play a pivotal role in mediating higher order Vpr-Vpr interactions. We therefore built models for higher order multimeric forms, and a hexamer model (Fig. 3C and Fig. 3D) exhibited an interface where all the three helices participated in interaction interfaces. In this hexamer model, both parallel and antiparallel dimeric units were present and the hydrophobic residues faced to interior of the helices (Fig. 3D).
HIV-1 Vpr is one of the non-structural proteins that is packaged in significant quantities in virus particles. Virion-associated Vpr is present in the infected cells prior to de novo synthesis and is known to cause the host cellular dysfunctions during early infection [17, 19, 42]. Studies have indicated that the p6 domain of Gag is critical for the incorporation of Vpr into virus particles [15, 39, 40, 46]. However, it is not clear whether Vpr oligomerization is a prerequisite for virion incorporation. As expected, chimeric Venus containing wild type Vpr and chimeric Venus containing Gag resulted in the reconstitution of Venus with fluorescence suggesting an interaction between these two proteins. On the other hand, chimeric Venus containing mutant Vpr failed to interact with Gag. Vpr mutants that showed oligomerization negative phenotype also failed to incorporate into virus particles. Several studies have reported that virus particle contains between 14-275 molecules of Vpr in comparison to approximately 2500-2750 molecules of Gag protein depending on the system and methods used [38, 47]. This suggests that low amount of Vpr to Gag may be due to the interaction restricted to the specific configuration of Gag. Several studies evaluated Vpr-Gag interaction and reported that helical domain I (residues E25 and A30), P35 and helical domain III (isoleucine-leucine residues) in Vpr are required for interaction with Gag, thus virion incorporation [26, 39, 48]. Our results on Vpr-Gag interaction using BiFC (Table 2) are in agreement with these studies and further supports the utility of BiFC assay for evaluating the interactions of Vpr with interacting partner proteins. Oligomerization defective mutants, A30L, Δ44, L68E and H71R lack the ability to incorporate into the virus particles, suggesting that Vpr oligomerization might be directly linked to virion associated Vpr functions, pathogenesis and disease progression. A very recent publication further confirms our findings that Vpr oligomerization is required for interaction with Gag and oligomerization deficient mutants of Gag interacted with Vpr .
An understanding of HIV-1 Vpr functions and its properties, in our view, is likely to shed light on the mechanisms involved in Vpr incorporation into the virus particle and how oligomerization feature influences infection of non dividing target cells. Although Vpr is not essential for virus replication in in vitro studies using established cell lines, it is well established that virion- associated Vpr play a major role in macrophage infection by aiding the transport of PIC into the nucleus [50, 51]. More importantly, virion-associated Vpr is known to mediate several host cellular events and immune evasive functions that are very similar to de novo synthesized Vpr [18, 52, 53]. This further bolsters the significance of virion-associated proteins present both in infectious and noninfectious particles and their role in HIV-1 pathogenesis. These studies further support the idea of developing potential therapeutic agents including small molecules against Vpr-Vpr interaction, Vpr-Gag interaction, virion incorporation and virion associated Vpr induced host cell dysregulation to combat HIV-1 infection.
This work was supported in part by the grant GM082251 from the NIAID, NIH.
- Cohen EA, Dehni G, Sodroski JG, Haseltine WA: Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J Virol. 1990, 64: 3097-3099.PubMedPubMed Central
- Connor RI, Chen BK, Choe S, Landau NR: Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology. 1995, 206: 935-944. 10.1006/viro.1995.1016.PubMedView Article
- Freed EO, Englund G, Martin MA: Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J Virol. 1995, 69: 3949-3954.PubMedPubMed Central
- Subbramanian RA, Kessous-Elbaz A, Lodge R, Forget J, Yao XJ, Bergeron D, Cohen EA: Human immunodeficiency virus type 1 Vpr is a positive regulator of viral transcription and infectivity in primary human macrophages. J Exp Med. 1998, 187: 1103-1111. 10.1084/jem.187.7.1103.PubMedPubMed CentralView Article
- Lum JJ, Cohen OJ, Nie Z, Weaver JG, Gomez TS, Yao XJ, Lynch D, Pilon AA, Hawley N, Kim JE, et al: Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J Clin Invest. 2003, 111: 1547-1554.PubMedPubMed CentralView Article
- Wang B, Ge YC, Palasanthiran P, Xiang SH, Ziegler J, Dwyer DE, Randle C, Dowton D, Cunningham A, Saksena NK: Gene defects clustered at the C-terminus of the vpr gene of HIV-1 in long-term nonprogressing mother and child pair: in vivo evolution of vpr quasispecies in blood and plasma. Virology. 1996, 223: 224-232. 10.1006/viro.1996.0471.PubMedView Article
- Yedavalli VR, Ahmad N: Low conservation of functional domains of HIV type 1 vif and vpr genes in infected mothers correlates with lack of vertical transmission. AIDS Res Hum Retroviruses. 2001, 17: 911-923. 10.1089/088922201750290032.PubMedView Article
- Yedavalli VR, Chappey C, Ahmad N: Maintenance of an intact human immunodeficiency virus type 1 vpr gene following mother-to-infant transmission. J Virol. 1998, 72: 6937-6943.PubMedPubMed Central
- Michael NL, Chang G, d'Arcy LA, Ehrenberg PK, Mariani R, Busch MP, Birx DL, Schwartz DH: Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus. J Virol. 1995, 69: 4228-4236.PubMedPubMed Central
- Saksena NK, Wang B, Ge YC, Xiang SH, Dwyer DE, Cunningham AL: Coinfection and genetic recombination between HIV-1 strains: possible biological implications in Australia and South East Asia. Ann Acad Med Singapore. 1997, 26: 121-127.PubMed
- Goh WC, Rogel ME, Kinsey CM, Michael SF, Fultz PN, Nowak MA, Hahn BH, Emerman M: HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med. 1998, 4: 65-71. 10.1038/nm0198-065.PubMedView Article
- Fritz JV, Didier P, Clamme JP, Schaub E, Muriaux D, Cabanne C, Morellet N, Bouaziz S, Darlix JL, Mely Y, de Rocquigny H: Direct Vpr-Vpr interaction in cells monitored by two photon fluorescence correlation spectroscopy and fluorescence lifetime imaging. Retrovirology. 2008, 5: 87-10.1186/1742-4690-5-87.PubMedPubMed CentralView Article
- Zhao LJ, Wang L, Mukherjee S, Narayan O: Biochemical mechanism of HIV-1 Vpr function. Oligomerization mediated by the N-terminal domain. J Biol Chem. 1994, 269: 32131-32137.PubMed
- Ali MH, Imperiali B: Protein oligomerization: how and why. Bioorg Med Chem. 2005, 13: 5013-5020. 10.1016/j.bmc.2005.05.037.PubMedView Article
- Jenkins Y, Pornillos O, Rich RL, Myszka DG, Sundquist WI, Malim MH: Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6(Gag). J Virol. 2001, 75: 10537-10542. 10.1128/JVI.75.21.10537-10542.2001.PubMedPubMed CentralView Article
- Poon B, Chen IS: Human immunodeficiency virus type 1 (HIV-1) Vpr enhances expression from unintegrated HIV-1 DNA. J Virol. 2003, 77: 3962-3972. 10.1128/JVI.77.7.3962-3972.2003.PubMedPubMed CentralView Article
- Tungaturthi PK, Sawaya BE, Singh SP, Tomkowicz B, Ayyavoo V, Khalili K, Collman RG, Amini S, Srinivasan A: Role of HIV-1 Vpr in AIDS pathogenesis: relevance and implications of intravirion, intracellular and free Vpr. Biomed Pharmacother. 2003, 57: 20-24. 10.1016/S0753-3322(02)00328-1.PubMedView Article
- Majumder B, Venkatachari NJ, Srinivasan A, Ayyavoo V: HIV-1 mediated immune pathogenesis: spotlight on the role of viral protein R (Vpr). Curr HIV Res. 2009, 7: 169-177. 10.2174/157016209787581445.PubMedView Article
- Andersen JL, Planelles V: The role of Vpr in HIV-1 pathogenesis. Curr HIV Res. 2005, 3: 43-51. 10.2174/1570162052772988.PubMedView Article
- Morellet N, Bouaziz S, Petitjean P, Roques BP: NMR structure of the HIV-1 regulatory protein VPR. J Mol Biol. 2003, 327: 215-227. 10.1016/S0022-2836(03)00060-3.PubMedView Article
- Wecker K, Morellet N, Bouaziz S, Roques BP: NMR structure of the HIV-1 regulatory protein Vpr in H2O/trifluoroethanol. Comparison with the Vpr N-terminal (1-51) and C-terminal (52-96) domains. Eur J Biochem. 2002, 269: 3779-3788. 10.1046/j.1432-1033.2002.03067.x.PubMedView Article
- Singh SP, Tomkowicz B, Lai D, Cartas M, Mahalingam S, Kalyanaraman VS, Murali R, Srinivasan A: Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr. J Virol. 2000, 74: 10650-10657. 10.1128/JVI.74.22.10650-10657.2000.PubMedPubMed CentralView Article
- Mahalingam S, Ayyavoo V, Patel M, Kieber-Emmons T, Weiner DB: Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr. J Virol. 1997, 71: 6339-6347.PubMedPubMed Central
- Mahalingam S, Patel M, Collman RG, Srinivasan A: The carboxy-terminal domain is essential for stability and not for virion incorporation of HIV-1 Vpr into virus particles. Virology. 1995, 214: 647-652. 10.1006/viro.1995.0079.PubMedView Article
- Mahalingam S, Collman RG, Patel M, Monken CE, Srinivasan A: Functional analysis of HIV-1 Vpr: identification of determinants essential for subcellular localization. Virology. 1995, 212: 331-339. 10.1006/viro.1995.1490.PubMedView Article
- Votteler J, Studtrucker N, Sorgel S, Munch J, Rucker E, Kirchhoff F, Schick B, Henklein P, Fossen T, Bruns K, et al: Proline 35 of human immunodeficiency virus type 1 (HIV-1) Vpr regulates the integrity of the N-terminal helix and the incorporation of Vpr into virus particles and supports the replication of R5-tropic HIV-1 in human lymphoid tissue ex vivo. J Virol. 2007, 81: 9572-9576. 10.1128/JVI.02803-06.PubMedPubMed CentralView Article
- Bourbigot S, Beltz H, Denis J, Morellet N, Roques BP, Mely Y, Bouaziz S: The C-terminal domain of the HIV-1 regulatory protein Vpr adopts an antiparallel dimeric structure in solution via its leucine-zipper-like domain. Biochem J. 2005, 387: 333-341. 10.1042/BJ20041759.PubMedPubMed CentralView Article
- Thotala D, Schafer EA, Tungaturthi PK, Majumder B, Janket ML, Wagner M, Srinivasan A, Watkins S, Ayyavoo V: Structure-functional analysis of human immunodeficiency virus type 1 (HIV-1) Vpr: role of leucine residues on Vpr-mediated transactivation and virus replication. Virology. 2004, 328: 89-100. 10.1016/j.virol.2004.07.013.PubMedView Article
- Comeau SR, Gatchell DW, Vajda S, Camacho CJ: ClusPro: a fully automated algorithm for protein-protein docking. Nucleic Acids Res. 2004, 32: W96-99. 10.1093/nar/gkh354.PubMedPubMed CentralView Article
- Comeau SR, Vajda S, Camacho CJ: Performance of the first protein docking server ClusPro in CAPRI rounds 3-5. Proteins. 2005, 60: 239-244. 10.1002/prot.20564.PubMedView Article
- Lyskov S, Gray JJ: The RosettaDock server for local protein-protein docking. Nucleic Acids Res. 2008, 36: W233-238. 10.1093/nar/gkn216.PubMedPubMed CentralView Article
- Mandell JG, Roberts VA, Pique ME, Kotlovyi V, Mitchell JC, Nelson E, Tsigelny I, Ten Eyck LF: Protein docking using continuum electrostatics and geometric fit. Protein Eng. 2001, 14: 105-113. 10.1093/protein/14.2.105.PubMedView Article
- Ten Eyck LF, Mandell J, Roberts VA, Pique M.E: Surveying molecular interactions with DOT. Proceedings of the 1995 ACM/IEEE Supercomputing Conference ACM Press, New York. Edited by: Hayes A, Simmons M. 1995
- Jin J, Sturgeon T, Chen C, Watkins SC, Weisz OA, Montelaro RC: Distinct intracellular trafficking of equine infectious anemia virus and human immunodeficiency virus type 1 Gag during viral assembly and budding revealed by bimolecular fluorescence complementation assays. J Virol. 2007, 81: 11226-11235. 10.1128/JVI.00431-07.PubMedPubMed CentralView Article
- Comeau SR, Camacho CJ: Predicting oligomeric assemblies: N-mers a primer. J Struct Biol. 2005, 150: 233-244. 10.1016/j.jsb.2005.03.006.PubMedView Article
- Bolton DL, Lenardo MJ: Vpr cytopathicity independent of G2/M cell cycle arrest in human immunodeficiency virus type 1-infected CD4+ T cells. J Virol. 2007, 81: 8878-8890. 10.1128/JVI.00122-07.PubMedPubMed CentralView Article
- Accola MA, Ohagen A, Gottlinger HG: Isolation of human immunodeficiency virus type 1 cores: retention of Vpr in the absence of p6(gag). J Virol. 2000, 74: 6198-6202. 10.1128/JVI.74.13.6198-6202.2000.PubMedPubMed CentralView Article
- Singh SP, Tungaturthi P, Cartas M, Tomkowicz B, Rizvi TA, Khan SA, Kalyanaraman VS, Srinivasan A: Virion-associated HIV-1 Vpr: variable amount in virus particles derived from cells upon virus infection or proviral DNA transfection. Virology. 2001, 283: 78-83. 10.1006/viro.2001.0849.PubMedView Article
- Bachand F, Yao XJ, Hrimech M, Rougeau N, Cohen EA: Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 gag precursor. J Biol Chem. 1999, 274: 9083-9091. 10.1074/jbc.274.13.9083.PubMedView Article
- Paxton W, Connor RI, Landau NR: Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J Virol. 1993, 67: 7229-7237.PubMedPubMed Central
- Malim MH, Emerman M: HIV-1 accessory proteins--ensuring viral survival in a hostile environment. Cell Host Microbe. 2008, 3: 388-398. 10.1016/j.chom.2008.04.008.PubMedView Article
- Le Rouzic E, Benichou S: The Vpr protein from HIV-1: distinct roles along the viral life cycle. Retrovirology. 2005, 2: 11-10.1186/1742-4690-2-11.PubMedPubMed CentralView Article
- Mologni D, Citterio P, Menzaghi B, Zanone Poma B, Riva C, Broggini V, Sinicco A, Milazzo L, Adorni F, Rusconi S, et al: Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients. Aids. 2006, 20: 567-574. 10.1097/01.aids.0000210611.60459.0e.PubMedView Article
- Lang SM, Weeger M, Stahl-Hennig C, Coulibaly C, Hunsmann G, Muller J, Muller-Hermelink H, Fuchs D, Wachter H, Daniel MM, et al: Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J Virol. 1993, 67: 902-912.PubMedPubMed Central
- Cui J, Tungaturthi PK, Ayyavoo V, Ghafouri M, Ariga H, Khalili K, Srinivasan A, Amini S, Sawaya BE: The role of Vpr in the regulation of HIV-1 gene expression. Cell Cycle. 2006, 5: 2626-2638. 10.4161/cc.5.22.3442.PubMedView Article
- Zhu H, Jian H, Zhao LJ: Identification of the 15FRFG domain in HIV-1 Gag p6 essential for Vpr packaging into the virion. Retrovirology. 2004, 1: 26-10.1186/1742-4690-1-26.PubMedPubMed CentralView Article
- Muller B, Tessmer U, Schubert U, Krausslich HG: Human immunodeficiency virus type 1 Vpr protein is incorporated into the virion in significantly smaller amounts than gag and is phosphorylated in infected cells. J Virol. 2000, 74: 9727-9731. 10.1128/JVI.74.20.9727-9731.2000.PubMedPubMed CentralView Article
- Yao XJ, Subbramanian RA, Rougeau N, Boisvert F, Bergeron D, Cohen EA: Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. J Virol. 1995, 69: 7032-7044.PubMedPubMed Central
- Fritz JV, Dujardin D, Godet J, Didier P, De Mey J, Darlix JL, Mely Y, de Rocquigny H: HIV-1 Vpr oligomerization but not that of Gag directs the interaction between Vpr and Gag. J Virol. 84: 1585-1596. 10.1128/JVI.01691-09.
- Nitahara-Kasahara Y, Kamata M, Yamamoto T, Zhang X, Miyamoto Y, Muneta K, Iijima S, Yoneda Y, Tsunetsugu-Yokota Y, Aida Y: Novel nuclear import of Vpr promoted by importin alpha is crucial for human immunodeficiency virus type 1 replication in macrophages. J Virol. 2007, 81: 5284-5293. 10.1128/JVI.01928-06.PubMedPubMed CentralView Article
- Sherman MP, Greene WC: Slipping through the door: HIV entry into the nucleus. Microbes Infect. 2002, 4: 67-73. 10.1016/S1286-4579(01)01511-8.PubMedView Article
- Poon B, Grovit-Ferbas K, Stewart SA, Chen IS: Cell cycle arrest by Vpr in HIV-1 virions and insensitivity to antiretroviral agents. Science. 1998, 281: 266-269. 10.1126/science.281.5374.266.PubMedView Article
- Arokium H, Kamata M, Chen I: Virion-associated Vpr of human immunodeficiency virus type 1 triggers activation of apoptotic events and enhances fas-induced apoptosis in human T cells. J Virol. 2009, 83: 11283-11297. 10.1128/JVI.00756-09.PubMedPubMed CentralView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.